GMA
Genmab A/S (GMAB) Q1 2026 Earnings
GMAB·Reported May 7, 2026·Before market open
Genmab A/S reported Q1 2026 revenue of $896.0M (+23.4% YoY), missed analyst consensus of $905.8M by $9.8M. Diluted EPS came in at $0.15 (-51.6% YoY).
Revenue
$896.0Mmissed by $9.8M
Consensus: $905.8MDiluted EPS
$0.15met estimate
Consensus: $0.15
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q1 2026 Earnings FAQ
Common questions about Genmab A/S's Q1 2026 earnings report.
Genmab A/S (GMAB) reported Q1 2026 earnings on May 7, 2026 before market open.
Genmab A/S reported revenue of $896.0M and diluted EPS of $0.15 for Q1 2026.
Revenue missed the consensus estimate of $905.8M by $9.8M. EPS beat the consensus estimate of $0.15 by $0.00.
Compared to the same quarter a year prior, revenue grew 23.4% from $726.0M a year earlier and diluted EPS declined 51.6% from $0.31.